Veradermics, Incorporated (MANE) Gets a Buy from LifeSci Capital
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Veradermics (MANE) with a $170 price target. Additionally, B. Riley Securities initiated coverage with a Buy rating and the same $170 target. The report highlights Katkhuda's strong track record as a 5-star analyst in the healthcare sector.
In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Veradermics, Incorporated, with a price target of $170.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Katkhuda is a 5-star analyst with an average return of 32.4% and a 58.62% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Disc Medicine, MoonLake Immunotherapeutics, and Eledon Pharmaceuticals.
In a report released today, B. Riley Securities also initiated coverage with a Buy rating on the stock with a $170.00 price target.